Literature DB >> 2402485

T-cell receptor-negative natural killer cells display antigen-specific cytotoxicity for microvascular endothelial cells.

J R Bender1, R Pardi, E Engleman.   

Abstract

Based upon prior demonstrations that human microvascular endothelial cells (ECs) could serve as natural killer (NK) cell targets, we established NK cell lines and clones by repeated stimulation of highly purified CD16-positive, CD3/T-cell receptor (Ti)-negative cells with allogeneic ECs. After 3 weeks in culture these lymphoid cells, which neither expressed surface CD3/Ti molecules nor rearranged Ti beta- or gamma-chain genes and which lysed K562 human erythroleukemia cells, displayed specific cytotoxicity for the stimulating ECs. Furthermore, freshly isolated NK cells bound and then removed from each of several allogeneic EC lines displayed selective cytotoxicity for the adsorbing EC line. These results provide evidence for alloantigen-specific recognition of microvascular ECs by NK cells that appears to be determined, at least in part, at the level of adherence. We discuss the implications of these findings with respect to the rejection of vascularized organ allografts.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2402485      PMCID: PMC54659          DOI: 10.1073/pnas.87.18.6949

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

2.  Activation of human thymocytes via the 50KD T11 sheep erythrocyte binding protein induces the expression of interleukin 2 receptors on both T3+ and T3- populations.

Authors:  D A Fox; R E Hussey; K A Fitzgerald; A Bensussan; J F Daley; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

3.  "Panning" for lymphocytes: a method for cell selection.

Authors:  L J Wysocki; V L Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

Review 4.  Human natural killer cells: biologic and pathologic aspects.

Authors:  G Trinchieri; B Perussia
Journal:  Lab Invest       Date:  1984-05       Impact factor: 5.662

5.  Genetics of the murine hemopoietic-histocompatibility system: an overview.

Authors:  G Cudkowicz; I Nakamura
Journal:  Transplant Proc       Date:  1983-12       Impact factor: 1.066

6.  In situ effector pathways of allograft destruction. 1. Generation of the "cellular" effector response in the graft and the graft recipient.

Authors:  A Nemlander; A Soots; P Häyry
Journal:  Cell Immunol       Date:  1984-12       Impact factor: 4.868

7.  Selective depletion of human natural killer cells on monolayers of target cells.

Authors:  W H Phillips; J R Ortaldo; R B Herberman
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

8.  Depletion of NK by cellular immunoadsorption.

Authors:  P J Jensen; H S Koren
Journal:  J Immunol       Date:  1979-09       Impact factor: 5.422

9.  A human alloreactive inducer T cell clone that selectively activates antigen-specific suppressor T cells.

Authors:  N Mohagheghpour; N K Damle; D K Moonka; C P Terrell; E G Engleman
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

10.  Target-effector interaction in the human and murine natural killer system: specificity and xenogeneic reactivity of the solubilized natural killer-target structure complex and its loss in a somatic cell hybrid.

Authors:  J C Roder; L Ahrlund-Richter; M Jondal
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

View more
  8 in total

1.  Induction of transporter associated with antigen processing by interferon gamma confers endothelial cell cytoprotection against natural killer-mediated lysis.

Authors:  O Ayalon; E A Hughes; P Cresswell; J Lee; L O'Donnell; R Pardi; J R Bender
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

2.  HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells.

Authors:  M Colonna; G Borsellino; M Falco; G B Ferrara; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

3.  Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancer.

Authors:  L T Vlasveld; E van de Wiel-van Kemenade; A J de Boer; J J Sein; M P Gallee; R T Krediet; C J Mellief; E M Rankin; A Hekman; C G Figdor
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 4.  Endothelial cells in allograft rejection.

Authors:  Rafia S Al-Lamki; John R Bradley; Jordan S Pober
Journal:  Transplantation       Date:  2008-11-27       Impact factor: 4.939

5.  Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression.

Authors:  Jonathan Merola; Melanie Reschke; Richard W Pierce; Lingfeng Qin; Susann Spindler; Tania Baltazar; Thomas D Manes; Francesc Lopez-Giraldez; Guangxin Li; Laura G Bracaglia; Catherine Xie; Nancy Kirkiles-Smith; W Mark Saltzman; Gregory T Tietjen; George Tellides; Jordan S Pober
Journal:  JCI Insight       Date:  2019-10-17

6.  Evidence for the involvement of CD56 molecules in alloantigen-specific recognition by human natural killer cells.

Authors:  N Suzuki; T Suzuki; E G Engleman
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

7.  Lymphocyte adhesion-dependent calcium signaling in human endothelial cells.

Authors:  S Pfau; D Leitenberg; H Rinder; B R Smith; R Pardi; J R Bender
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

8.  Antigen-receptor complex stimulation triggers protein kinase C-dependent CD11a/CD18-cytoskeleton association in T lymphocytes.

Authors:  R Pardi; L Inverardi; C Rugarli; J R Bender
Journal:  J Cell Biol       Date:  1992-03       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.